GLP1R and atherosclerosis: In 2015, when relatively few relevant CV outcome trial data were available, an understandably lower use of GLP-1 RAs (7.9%) and SGLT2is (8.8%) was reported in over 500,000 US adults with T2D and established ASCVD [10].